The Biotech and Biomedical to Oncology (BIO2Oncology) program is CEA’s technology accelerator program aimed at supporting innovative projects from ideation to market. Regardless of the stage of the technology, innovators may engage with BIO2Oncology to have their ideas or technology evaluated by an Expert Review Board (ERB) comprised of experienced entrepreneurial researchers and clinicians, in addition to industry and commercialization experts. Based on this evaluation and feedback, projects given the “green light” will work with BIO2Oncology to develop a plan aimed to improve the odds of commercialization based on ERB and other stakeholder feedback and recommendations.
Entrepreneur contacts CEA and is provided a link to complete the BIO2Oncology Application and provides preliminary details for the project to begin the process.
BIO2Oncology staff will meet with Entrepreneur(s) to explain the process, gather more details around the project and commercialization potential in order to determine evaluation readiness. Based on this engagement, the Entrepreneur will be asked to complete a more comprehensive project package for evaluation.
Experienced panel of faculty entrepreneurs, internal stakeholders, and external experts evaluate the project and provide feedback on project design, commercial potential, and pathway milestones for needed to move to market. This includes direct engagement with the entrepreneur to discuss the project and provide valuable insight on project needs and/or potential.
For projects determined to have commercial potential and given “green light” status, BIO2Oncology staff will collaborate with the entrepreneur to develop the necessary steps to move forward including educational needs, internal and external connections, and mentoring needs. For projects that need more development or iteration, BIO2Oncology will work with the Entrepreneur(s) to educate them on ways to improve future projects to increase commercialization potential.
Entrepreneur(s) will meet regularly and/or as needed with BIO2Oncology staff to review progress, address questions, provide accountability, and evaluate the innovation plan strategy to support the potential for positive movement of the technology forward towards commercialization.
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.